Radiopharmaceutical Ligands and Tracers

  • Mark S. George
  • Howard A. Ring
  • Durval C. Costa
  • Peter J. Ell
  • Kypros Kouris
  • Peter H. Jarritt


In recent years improvements in instrumentation and radiopharmaceutical developments have broadened the scope of single-photon emission tomography (SPET) of the brain. Patients with neurological and psychiatric diseases may be better assessed. More objective parameters (i.e. brain perfusion, neuroreceptor availability, neurotransmitter utilization) can now be used to study the natural progression of disease and to determine its response to either established or new therapeutic interventions.


Multiple System Atrophy Brain Perfusion SPET Study Physiological Agonist Ethyl Cysteinate 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Baker JHL, Campbell JK, Houser OW, et al (1974) Computer assisted tomography of the head. An early evaluation. Mayo Clin Proc 49:17–27PubMedGoogle Scholar
  2. Biersack HJ, Coenen HH, Stöcklin G, et al (1989) Imaging of brain tumours with L-3-[123I]Iodo-methyl tyrosine and SPECT. J Nucl Med 30:110–112PubMedGoogle Scholar
  3. Black HL, Hawkins RA, Kim KT, et al (1989) Thallium-201 (SPECT): a quantitative technique to distinguish low grade from malignant brain tumours. J Neurosurg 71:342–346PubMedCrossRefGoogle Scholar
  4. Bloom FE (1985) Neurotransmitter diversity and its functional significance. J R Soc Med 78:189–192PubMedGoogle Scholar
  5. Bossuyt A, Pirotte R, Chirico A, et al (1990a) Whole body dosimetry of Tc-99m-MRP 20: the result of a phase I clinical trial. Eur J Nucl Med 16:432Google Scholar
  6. Bossuyt A, Pirotte R, Chirico A, et al (1990b) Tc-99m-MRP 20, a new brain perfusion agent suitable for SPECT imaging. Eur J Nucl Med 16:418Google Scholar
  7. Bossuyt A, Pirotte R, Carroll MJ, et al (1991) Tc-99m-MRP 20, a new brain perfusion agent suitable for SPECT imaging. In: Schmidt HAE, van der Schoot JB (eds) Nuclear medicine. The state of the art of nuclear medicine in Europe. Schattauer, Stuttgart New York, pp 222–224Google Scholar
  8. Bradbury MWB (1985) Transport across the cerebral endothelium. Circ Res 57:213–222PubMedGoogle Scholar
  9. Carril JM, MacDonald AF, Dendy PP, et al (1979) Clinical scintigraphy: value of adding emission computed tomographic studies to conventional pertechnetate images (512 cases). J Nucl Med 20:1117–1123PubMedGoogle Scholar
  10. Clark SEM, Harding K, Buxton TM (1990) The current cost of nuclear medicine. Nucl Med Commun 11:527–538CrossRefGoogle Scholar
  11. Costa DC, Ell PJ, Cullum ID, et al (1986) The in vivo distribution of 99Tcm-HM-PAO in normal man. Nucl Med Commun 7:647–658PubMedGoogle Scholar
  12. Costa DC, Verhoeff NPLG, Cullum ID, et al (1990) In vivo characterisation of 3-iodo-6-methoxybenzamide 123-I in humans. Eur J Nucl Med 16:813–816PubMedCrossRefGoogle Scholar
  13. Crawley JCW, Smith T, Veall N, et al (1983) Dopamine receptors displayed in living human brain with 77Br-p-bromospiperone. Lancet I:975CrossRefGoogle Scholar
  14. Deland FH (1971) Scanning in cerebral vascular disease. Semin Nucl Med 1:31–40PubMedCrossRefGoogle Scholar
  15. Dempsey EW, Wislocki GB (1955) An electron microscopic study of the blood-brain barrier in the rat. J Biophys Biochem Cytol 1:245PubMedCrossRefGoogle Scholar
  16. Ell PJ, Deacon JM, Ducassou D, et al (1980) Emission and transmission brain tomography. BMJ 280:438–440PubMedCrossRefGoogle Scholar
  17. Ell PJ, Cullum I, Costa DC, et al (1985) A new regional cerebral blood flow mapping with Tc-99m-labelled compound. Lancet 11:50–51CrossRefGoogle Scholar
  18. Fischer RJ, Miale A Jr (1972) Evaluation of cerebral vascular disease with radionuclide angiography. Stroke 3:1–9PubMedCrossRefGoogle Scholar
  19. Glasco JL, Currier RD, Goodrich JK, et al (1965) Brain scans at varied intervals following CVA. J Nucl Med 6:902–916Google Scholar
  20. Gruber ML, Hochberg FH (1990) Editorial: systematic evaluation of primary brain tumours. J Nucl Med 31:969–971PubMedGoogle Scholar
  21. Hill TC, Lovett RD, Zimmerman RE (1980) Quantification of Tc-99m glucoheptonate uptake in brain lesions with emission-computed tomography. In: Single photon emission computed tomography and other selected computer topics. Society of Nuclear Medicine, New York, pp 169–176Google Scholar
  22. Holman BL, Hellman RS, Goldsmith SJ, et al (1989) Biodistribution, dosimetry and clinical evaluation of technetium-99m ethyl cysteinate dimer in normal subjects and in patients with chronic cerebral infarction. J Nucl Med 30:1018–1024PubMedGoogle Scholar
  23. Hopkins GG, Kristensen KAB (1973) Rapid sequential scintiphotography in the radionuclide detection of subdural hematoma. J Nucl Med 14:288–290PubMedGoogle Scholar
  24. Hounsfield GN (1973) Computerised transverse axial scanning (tomography): Part 1. Description of system. Br J Radiol 46:1016–1022PubMedCrossRefGoogle Scholar
  25. Hung JC, Volkert WA, Holmes RA (1989) Stabilization of technetium-99m-D,L-hexamethylpropyleneamineoxime (99mTc-D,L-HMPAO) using gentisic acid. Nucl Med Biol 16:675–680Google Scholar
  26. Iversen LL (1982) Neurotransmitters and CNS disease. The Lancet II:914–918CrossRefGoogle Scholar
  27. Kaplan WD, Takronan T, Morris H, et al (1989) Thallium-201 brain tumour imaging: a comparative study with pathologic correlation. J Nucl Med 28:47–52Google Scholar
  28. Kim KT, Black KL, Marciano D, et al (1990) Thallium-201 SPECT imaging of brain tumours: methods and results. J Nucl Med 31:965–969PubMedGoogle Scholar
  29. Knapp WH, Von Kummaer R, Kubler W (1986) Imaging of cerebral blood flow-to-volume distribution using SPECT. J Nucl Med 27:465–470PubMedGoogle Scholar
  30. Kung HF, Blau M (1980) Synthesis of selenium-75 labelled tertiary diamines: new brain imaging agents. J Med Chem 23:1127–1130PubMedCrossRefGoogle Scholar
  31. Léveillé J, Demonceau G, De Roo M, et al (1989) Characterization of technetium-99m-L, L-ECD for brain perfusion imaging, part 2. Biodistribution and brain imaging in humans. J Nucl Med 30:1902–1910PubMedGoogle Scholar
  32. Libson K, Messa C, Kwiatkowski M et al (1989) 99mTc-MRP-20. A new class of neutral complex with implications for brain scintigraphy. J Nucl Med All Sci 33:305–306Google Scholar
  33. Maynard CD, Witcofski RL, Janeway R et al (1969) Radioisotopic arteriography as an adjunct to the brain scan. Radiology 92:908–912PubMedGoogle Scholar
  34. Mazière B, Mazière M (1990) Where have we got with neuroreceptor mapping of the human brain? Eur J Nucl Med 16:817–835PubMedCrossRefGoogle Scholar
  35. Miller JW, Hess A (1958) The blood-brain barrier: an experimental study with vital dyes. Brain 81:248CrossRefGoogle Scholar
  36. Morgan GF, Thornback JR, Deblaton M et al (1990) Development of a novel class of lipophilic technetium complexes designed to mimic rCBF (abstract 131). Eur J Nucl Med 16:423Google Scholar
  37. Mountz JM, Stafford-Schuck K, McKeeven PE, et al (1988) Thallium-201 tumour/cardiac ratio estimation of residual astrocytoma. J Neurosurg 68:705–709PubMedCrossRefGoogle Scholar
  38. Neirinckx RD, Canning LR, Piper IM, et al (1987) Technetium-99m, d, 1-HM-PAO: a new radiopharmaceutical for SPECT imaging of regional cerebral blood perfusion. J Nucl Med 18:191–202Google Scholar
  39. Perry EK (1991) Neurotransmitters and diseases of the brain. Br J Hosp Med 45:73–83PubMedGoogle Scholar
  40. Reese TS, Karnovski MJ (1968) Fine structural localisation of a blood-brain barrier to exogenous peroxidase. J Cell Biol 34:207CrossRefGoogle Scholar
  41. Rollo FD, Cavalieri RR, Born M, et al (1977) Comparative evaluation of 99mTcGH, 99mTcO4 and 99mTcDTPA as brain imaging agents. Radiology 123:379–383PubMedGoogle Scholar
  42. Ryerson TW, Spies SM, Singh NB, et al (1978) A quantitative clinical comparison of three 99mtechnetium labelled brain imaging radiopharmaceuticals. Radiology 127:429–432PubMedGoogle Scholar
  43. Sharp FF, Smith FW, Gemmell HG, et al (1986) Technetium-99m-HM-PAO stereoisomers as potential agents for imaging regional cerebral blood flow: human volunteer studies. J Nucl Med 27:171–177PubMedGoogle Scholar
  44. Siccardi AG, Buraggi GL, Natali PG, et al (1989) Technetium-99m-ECD: a new brain imaging agent: in vivo kinetics and biodistribution studies in normal human subjects. J Nucl Med 30:599–604Google Scholar
  45. Uzler JM, Bennett LR, Mena I, et al (1975) Human CNS perfusion scanning with 123I-iodoantipyrine. Radiology 115:197–200Google Scholar
  46. Van Nerom C, Bormans G, De Beukelaer C, et al (1990) Metabolism of 9mTc-ECD in organ homogenates of baboon. In: Schmidt HAE, Chambron PD (eds) Nuclear medicine. Quantitative analysis in imaging and function. Schattauer, Stuttgart New York, pp 87–89Google Scholar
  47. Van Royen EA, De Bruine JF, Hill TC, et al (1987) Cerebral blood flow imaging with thallium-201 diethyldithiocarbamate SPECT. J Nucl Med 28:178–183PubMedGoogle Scholar
  48. Verbruggen AM (1990) Radiopharmaceuticals: state of the art. Eur J Nucl Med 17:346–364PubMedCrossRefGoogle Scholar
  49. Verhoeff NPGL (1991) Pharmacological implications for neuroreceptor imaging. Eur J Nucl Med (in press)Google Scholar
  50. Vyth A, Fennema PJ, Van der Schoot JB (1983) 201Tl-diethyldithiocarbamate: a possible radiopharmaceutical for brain imaging. Pharmacol Weekbl Sci 5:213–216CrossRefGoogle Scholar
  51. Wagner HN, Burner HD, Dannals RF, et al (1983) Imaging dopamine receptors in the human brain by PET. Science 221:1264–1266PubMedCrossRefGoogle Scholar
  52. Walovitch RC, Williams SJ, Lafrance ND (1990) Radiolabelled agents for SPECT imaging of brain perfusion. Nucl Med Biol 17:77–83Google Scholar
  53. Waxman AD, Tanacescu D, Siemsen JK, et al (1976) Technetium-99m glucoheptonate as a brain scanning agent: critical comparison with pertechnetate. J Nucl Med 17:345–348PubMedGoogle Scholar
  54. White DR, Muss HB, Cowan RJ (1976) Brain scanning in patients with advanced lung cancer. Clin Nucl Med 1:93–96CrossRefGoogle Scholar

Copyright information

© Springer-Verlag London Limited 1991

Authors and Affiliations

  • Mark S. George
    • 1
    • 2
  • Howard A. Ring
    • 3
  • Durval C. Costa
    • 4
  • Peter J. Ell
    • 5
  • Kypros Kouris
    • 6
    • 7
  • Peter H. Jarritt
    • 8
  1. 1.Raymond Way Neuropsychiatry Research Group, Department of Clinical NeurologyInstitute of NeurologyLondonEngland
  2. 2.Department of Psychiatry and Behavioral SciencesMedical University of South CarolinaCharlestonUSA
  3. 3.Raymond Way Neuropsychiatry Research Group, Department of Clinical NeurologyInstitute of NeurologyLondonEngland
  4. 4.Institute of Nuclear MedicineUniversity College and Middlesex School of Medicine (UCMSM)LondonEngland
  5. 5.Institute of Nuclear MedicineUniversity College and Middlesex School of Medicine (UCMSM)LondonEngland
  6. 6.Institute of Nuclear MedicineUniversity College and Middlesex School of Medicine (UCMSM)LondonEngland
  7. 7.University of KuwaitKuwait CityKuwait
  8. 8.Institute of Nuclear MedicineUniversity College and Middlesex School of Medicine (UCMSM)LondonEngland

Personalised recommendations